

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6: G01N		A2	(11) International Publication Number: WO 97/26523
			(43) International Publication Date: 24 July 1997 (24.07.97)
(21) International Application Number: PCT/US97/00881		(81) Designated States: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KG, KP, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SL, SK, TJ, TM, TR, TT, UA, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patents (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 17 January 1997 (17.01.97)		Published <i>Without international search report and to be republished upon receipt of that report.</i>	
(30) Priority Data: 08/588,526 18 January 1996 (18.01.96) US			
(71) Applicant: PROGENITOR, INC. [US/US]; 1507 Chambers Road, Columbus, OH 43212 (US).			
(72) Inventors: SNODGRASS, H., Ralph; 650 Retreat Lane, Powell, OH 43065 (US). CIOFFI, Joseph; 1180 Bayboro Drive, New Albany, OH 43054 (US). ZUPANCIC, Thomas, J.; 501 Park Boulevard, Worthington, OH 43085 (US). SHAFFER, Alan, W.; 256 Lakeview Drive, Lancaster, OH 43130 (US).			
(74) Agents: POISSANT, Brian, M. et al.; Pennie & Edmonds, 1155 Avenue of the Americas, New York, NY 10036 (US).			
(54) Title: DETECTION OF A LEPTIN RECEPTOR VARIANT AND METHODS FOR REGULATING OBESITY			
(57) Abstract			
<p>The present invention relates to a variant form of the receptor for the <i>obese</i> gene product. In particular, the invention relates to methods of detecting this receptor variant in cells and tissues of obese individuals. In addition, it relates to methods of inhibiting or down-regulating expression of this variant in cells to augment their responsiveness to weight regulation by leptin as well as methods of using compounds to directly activate signal transduction pathways associated with this ligand-receptor system.</p>			

BEST AVAILABLE COPY

